Bakay, U.; İzci Duran, T. Real-World Effectiveness and Safety of Upadacitinib in Tumor Necrosis FactorInhibitor Refractory Axial Spondyloarthritis: 52-Week Outcomes from a Single-Center Cohort. Archives of Rheumatology 2025, 40, 465-473.